Firebrick Pharma Limited (AU:FRE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Ltd has extended its consulting agreement with Keith Shortall to boost sales of Nasodine in Singapore and explore partnerships across Asia. The six-month extension, starting in January 2025, includes a grant of 1.5 million share options to Shortall, contingent on meeting specific sales and partnership targets. This move signals Firebrick’s strategic push to strengthen its presence in the Asian pharmaceutical market.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.